Advisory Board HF EMEA Cross - divisional with Abbott HF, EP, CRM , and SH Divisions Date - September 1 3 th (arrival and dinner on 1 2 th ) Zaventem, Belgium (Da Vincilaan 9 – 1935 Zaventem). Dear all, Abbott has a strong offer in terms of portfolio of therapy solutions for H eart F ailure Our organization is structurally focusing on parts of th e Abbott HF portfolio and we would like to “ enlarge the zoom ” for this discussion with you to understand what we could do more and better to become the undisputed leader in medical devices in Heart F ailure. Please join us for this intense exchange on Heart Failure ! Agenda Time Topic Presenter 8 .30 – 8 4 5 Welcome and Agenda xxx 8 4 5 – 9 1 5 Round of Introductions All 9 1 5 – 1 0 1 5 Where are we today from a physician perspective ? • HF landscape “ today and tomorrow ” • K ey challenges in HF • How is Abbott perceived today? xxx 1 0 1 5 – 1 0 3 0 Break 1 0 3 0 – 1 1 30 Abbott HF Portfolio: opportunities and challenges xxx 1 1 30 – 1 2 30 Drugs and devices • O ptimizing drug treatment thanks to implanted devices • How to increase patient access to device therapies ? xxx 1 2 30 – 1 3 1 5 Lunch Buffet 1 3 1 5 – 1 4 45 The Patient Pathway – how to improve it? x xx 1 4.4 5 – 15. 00 Break 15. 00 – 16. 00 Improving the leverage on the Abbott portfolio xxx 16. 00 – 16.45 Becoming the leader in medical devices for Heart Failure – what should we do more? xxx 16.45 – 17.00 Closing and Next Steps xxx